ENTA - CIK 0001177648
ENANTA PHARMACEUTICALS INC (ENTA) reported revenue of $65.32M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $65.32M | -3.4% |
| FY 2024 | $67.64M | -14.6% |
| FY 2023 | $79.20M | -8.1% |
| FY 2022 | $86.16M | -11.2% |
| FY 2021 | $97.07M | -20.7% |
| FY 2020 | $122.47M | -40.3% |
| FY 2019 | $205.20M | -0.7% |
| FY 2018 | $206.63M | +101.0% |
| FY 2017 |
ENANTA PHARMACEUTICALS INC (ENTA) reported revenue of $65.32M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, ENANTA PHARMACEUTICALS INC's revenue grew from $41.88M to $65.32M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $102.81M |
| +16.5% |
| FY 2016 | $88.27M | -45.1% |
| FY 2015 | $160.88M | +237.0% |
| FY 2014 | $47.74M | +48.9% |
| FY 2013 | $32.05M | -23.1% |
| FY 2012 | $41.71M | -0.4% |
| FY 2011 | $41.88M | - |